Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59443
Hammerman, P S; Sos, M L; Ramos, A H; Xu, C; Dutt, A; Zhou, W; Brace, L E; Woods, B A; Lin, W; Zhang, J; Deng, X; Lim, S M; Heynck, S; Peifer, M; Simard, J R; Lawrence, M S; Onofrio, R C; Salvesen, H B; Seidel, D; Zander, T; Heuckmann, J M; Soltermann, A; Moch, H; Koker, M; Leenders, F; Gabler, F; Querings, S; Ansén, S; Brambilla, E; Brambilla, C; Lorimier, P; Brustugun, O T; Helland, A; Petersen, I; Clement, J H; Groen, H; Timens, W; Sietsma, H; Stoelben, E; Wolf, J; Beer, D G; Tsao, M S; Hanna, M; Hatton, C; Eck, M J; Janne, P A; Johnson, B E; Winckler, W; Greulich, H; Bass, A J; Cho, J; Rauh, D; Gray, N S; Wong, K K; Haura, E B; Thomas, R K; Meyerson, M (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery, 1(1):78-89.
PDF - Registered users only
While genomically targeted therapies have improved outcomes for patients with lung adenocarcinoma, little is known about the genomic alterations which drive squamous cell lung cancer. Sanger sequencing of the tyrosine kinome identified mutations in the DDR2 kinase gene in 3.8% of squamous cell lung cancers and cell lines. Squamous lung cancer cell lines harboring DDR2 mutations were selectively killed by knock-down of DDR2 by RNAi or by treatment with the multi-targeted kinase inhibitor dasatinib. Tumors established from a DDR2 mutant cell line were sensitive to dasatinib in xenograft models. Expression of mutated DDR2 led to cellular transformation which was blocked by dasatinib. A squamous cell lung cancer patient with a response to dasatinib and erlotinib treatment harbored a DDR2 kinase domain mutation. These data suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib. As dasatinib is already approved for use, these findings could be rapidly translated into clinical trials.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology|
|DDC:||610 Medicine & health|
|Deposited On:||26 Feb 2012 19:53|
|Last Modified:||29 Nov 2013 10:00|
|Publisher:||American Association for Cancer Research|
|Citations:||Web of Science®. Times Cited: 124|
Scopus®. Citation Count: 154
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page